Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder
Phase 2
Completed
- Conditions
- Bladder Cancer
- Interventions
- Procedure: Robotic-assisted laparoscopic surgery
- First Posted Date
- 2009-08-24
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00963859
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia
Phase 1
Withdrawn
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: Influenza Vaccine Trivalent Inactivated (TIV)Drug: Pegylated interferon (PEGrIFN-α, Pegasys)Drug: Interferon (IFNα, Roferon-A)
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2012-08-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00962715
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 47
- Registration Number
- NCT00960752
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00960544
NOV-002 in Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2009-08-18
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00960726
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Phase 2
Completed
- Conditions
- LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2015-04-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 22
- Registration Number
- NCT00958256
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Preoperative Treatment With Cetuximab and/or IMC-A12
Phase 2
Completed
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT00957853
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cidofovir Instillation in Hematopoietic Stem Cell Transplant (HSCT) Recipients With Hemorrhagic Cystitis
- First Posted Date
- 2009-08-11
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00956176
STAT3 Inhibitor for Solid Tumors
- First Posted Date
- 2009-08-10
- Last Posted Date
- 2013-02-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00955812
- Locations
- 🇺🇸
Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, United States
🇺🇸UT MD Anderson Cancer Center, Houston, Texas, United States
Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Phase 1
Active, not recruiting
- Conditions
- Recurrent Head and Neck CarcinomaRecurrent Salivary Gland CarcinomaRecurrent Skin CarcinomaSkin Squamous Cell Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2009-08-07
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00954226
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States